Numerous studies indicate that p300 acts as a key transcriptional cofactor in vivo, at least, in part, by modulating activities of p53 by acetylation. Nevertheless, the regulation of the p53-p300 interplay is not completely understood. Here, we have identified the DEAD (Asp-Glu-Ala-Asp) box RNA helicase 24 (DDX24) as a novel regulator of the p300-p53 axis. We found that DDX24 interacts with p300, and this interaction leads to suppression of p300-mediated acetylation of p53. Notably, RNA interference-mediated knockdown of endogenous DDX24 significantly increases the acetylation levels of endogenous p53 in human cancer cells and subsequently promotes p53-mediated activation of its transcriptional targets such as p21 and p53 upregulated modulator of apoptosis (PUMA). In contrast, DDX24 expression inhibits the p300-p53 interaction and suppresses p300-mediated acetylation of p53. Moreover, DDX24 is overexpressed in human cancer cells and reduction of DDX24 protein levels by RNA interference induces cell cycle arrest and senescence in a p53-dependent manner. These results reveal DDX24 as an important regulator of p300 and suggest that the modulation of the p53-p300 interplay by DDX24 is critical in controlling p53 activities in human cancer cells.
INTRODUCTION
The p53 tumor suppressor protein provides powerful intrinsic defense mechanism against cancer, and mutations in p53 are the most frequent genetic alterations in human cancers. 1 p53 is kept in a latent form under normal condition until cells encounter stresses. The various stimuli from intrinsic and extrinsic environment lead to p53 activation and the activated p53 in turn controls cell cycle arrest, apoptosis, senescence and other responses yet to be identified to obstruct tumor cell growth. Although the precise mechanisms of p53 activation are not fully understood, they are generally believed to involve post-translational modifications, of which p53 acetylation has been most studied and proved indispensable for p53 transcriptional activity. 2, 3 Most strikingly, when all the major acetylation lysine sites of p53 were mutated to acetylation-defective arginine, p53-mediated classic cellular functions were entirely abrogated. 4 Acetylation provides multifaceted mechanism for p53 activation. This modification impairs the interaction between p53 and MDM2, the main negative regulatory E3 ubiquitin ligase of p53, to relieve both ubiquitin-dependent and ubiquitin-independent repression mediated by MDM2 from p53. 2, 5 p53 acetylation also augments DNA-binding affinity and possibly recruits cofactors to enable promoter-specific p53 transcriptional activity. 2, 6, 7 p53 acetylation occurs on multiple lysine sites and are catalyzed by histone acetyl transferases (HATs) including structurally related p300 and CREB-binding protein (CBP), p300/CBP-associated factor (PCAF), Tat-interactive protein of 60 kDa (Tip60) and human males absent On the First (hMOF). 2 p300/CBP, the first identified p53 acetyl transferase, has been proved a critical one in catalyzing multiple sites including six lysines (370, 372, 373, 381, 382 and 386) clustered at the C terminus and lysine 164 in the DNAbinding domain of p53. 4, 8 In addition, p300/CBP targets many other transcriptional factors, such as GATA-1 and c-Myc, and histones for acetylation to modulate global transcription activities. 9, 10 The critical role of p300/CBP in the regulation of global gene transcription was demonstrated by the embryonic lethality of conventional p300 or CBP knockout mice. 11 p300/CBP has been implicated in cancer development as many of its substrates are cancer molecules. However, the exact role has been under debate for quite a long time owing to the limited genetic evidence. p300 promotes cancer cell proliferation by progressing G1/S transition and the downregulation of p300 results in growth inhibition. 12 Conversely, p300 mutations, albeit at low frequency, in colorectal and breast cancers, support p300 as a classic tumor suppressor gene. 9, 13 Until recently, the tumor suppressor role of p300 has been substantiated by the evidence from large-scale tumor sequencing projects. p300 and CBP gene mutations, especially mutations clustered around the sequence encoding the HAT domain have been frequently found in multiple types of human tumors, including non-small cell lung cancers, acute lymphoblastic leukemia and B-cell lymphoma. [14] [15] [16] Presumably, p300 behaves as a tumor suppressor protein through the acetylation of its HAT substrates involved in cancer development, particularly, tumor suppressor proteins such as p53. In fact, the molecular network surrounding the p300-p53 axis remains not fully understood as p300 often exists in multicomponent complex. It is critical to resolve the molecular complexity of p300 complex to allow comprehensive understanding of the tumor suppressive role of p300 and how it attributed to p53 function. 17 Here we show that a novel interacting protein of p300, DEAD (Asp-Glu-Ala-Asp) box RNA helicase 24 (DDX24), identified from purified p300 complex, acts as a negative regulator of p53.
DDX24 is a family member of the DEAD box containing RNA helicases. 18 DEAD box proteins are a large group of putative RNA helicases and have been characterized in a variety of organisms ranging from bacteria to humans. 18 The DEAD box RNA helicases share nine conserved motifs in core region and one of the motifs bears the sequence Asp-Glu-Ala-Asp (DEAD) that inspires the family name. 19 The characteristic functions of this family are involved in RNA metabolic processes, such as transcription, pre-messenger RNA processing, RNA degradation, RNA export, ribosomal biogenesis and translation. 20, 21 However, relatively few members have been documented truly to be RNA helicases. 22 The physiological functions and regulatory data are presently lacking for most of the DEAD box proteins. 21, 22 Emerging evidence has started to link DEAD box proteins to cancer development and progression. 19, 21, 23 Several DEAD box proteins appear aberrantly expressed in cancer tissues and are reported to be involved with other cancer proteins or pathways. 21, [23] [24] [25] [26] In this report, we identified DEAD box protein DDX24 as a negative regulator of tumor suppressor protein p53. Endogenous DDX24 and p300 co-immunoprecipitate from nuclear extracts and DDX24 antagonizes the acetylation activity of p300 toward p53. RNA interference knockdown of DDX24 significantly elevates p53 acetylation level and subsequently p53 transcriptional activity with the most prominent effect on the p53 target gene p21. Consequently, DDX24 deficiency in human cancer cells leads to G1/S cell cycle arrest and ultimately triggers senescence. Of note, the frequent overexpression of DDX24 protein throughout breast tumor cell lines suggests a potential oncogenic role of DDX24 in breast cancer tumorigenesis.
RESULTS

Identification of DDX24 as a component in p300 protein complex
We previously made the initial efforts to explore endogenous p300 complex extracted from Hela cells and the following mass spectrometry analysis identified peptides specific for DDX24, an uncharacterized DEAD box RNA helicase, as one of the components in p300 protein complex. 27 However, no further exploration has been made on this putative novel interaction. We first sought to confirm the interaction by performing co-immunoprecipitation assays in H1299 cells transfected with Flag-p300 and/or Myc-DDX24 expression vectors. The western blot analysis of M2/Flag immunoprecipitates revealed that Myc-DDX24 specifically appeared in the Flag-p300 immunoprecipitates (Figure 1a ). To further examine the interaction of endogenous DDX24 and p300, we used U2OS osteosarcoma cells and performed p300 or control immunoglobulin G immunoprecipitation in nucleic fractions as both p300 and DDX24 predominantly reside in the nucleus. As expected, DDX24 readily co-precipitated with p300 ( Figure 1b ). Taken together, these data confirmed that DDX24 is a bona fide binding partner of p300.
By sequence alignment, we characterized that the multiplemotif helicase domain of DDX24 clustered in a central core region and encompasses amino acids 200-700 ( Figure 1c ). Both aminoand carboxyl-terminal fragments flanking the core domain of DDX24 are highly variable and unique regions, which are presumably regulatory domains for post-translational modifications and protein-protein interaction. 19 We performed an extended analysis to map the p300 interacting domain on DDX24 by generating a series of Myc-tagged DDX24 truncation mutants as diagrammed in Figure 1c . Flag/M2 agarose-conjugated p300 were incubated with DDX24 mutants-expressing H1299 cell lysates. The first 300 amino acids in DDX24, which includes the N-terminal flexible sequence and the first two conserved motifs, Q-motif and motif I, in helicase domain of DDX24, are sufficient for p300 interaction (Figure 1d ). Furthermore, all three tandem deletion mutants (FLdel1(Δ193-214aa), FLdel2(Δ215-239aa) and FLdel3 (Δ240-264aa)) disruptive in Q-motif or motif I of full-length DDX24 completely abolished p300 interaction ( Figure 1d ). Taken together, the N-terminal end specific for DDX24 and the partial helicase domain containing Q-motif and motif I mediate the interaction with p300. Notably, DDX24 is a unique interacting partner of p300 as the majority of the proteins co-purified with p300 are either DNA damage response or repair proteins. 27 DDX24 is a negative regulator of p53 transcriptional activity Previous studies have demonstrated that p300 directly catalyzes lysine acetylation on p53 to boost its transcriptional activity. Moreover, p300 localizes to the promoter region of p53 target genes to acetylate histones in the vicinity of the basic transcription machinery to favor a more accessible chromatin structure, thus to facilitate the transcription activity of p53. 3, 4, 8, 28, 29 As DDX24 apparently interacts with p300, we expect that endogenous DDX24 modulates p53 transcription activity. In Figure 2a , RNA interference-mediated knockdown of DDX24 in U2OS cells significantly augmented expression level of p21 and p53 upregulated modulator of apoptosis (PUMA), the classic p53 targets in regulating cell cycle arrest and apoptosis. Therefore, DDX24 acts as a negative modulator of p53 transcriptional activity.
To explore further, both control and DDX24 small interfering RNA (siRNA)-treated cells were incubated with 20 μM etoposide for 8 h and the increased expression of p21 and PUMA was recapitulated in DDX24-depleted cells (Figure 2a ). These data suggest that DDX24 negatively regulates p53 activity not only under normal condition but also upon DNA damage stress. We further confirmed that DDX24 ablation affected p53 targets at the transcriptional level by examining the messenger RNA level of p53 targets using quantitative reverse transcription-PCR ( Figure 2b) . DDX24 deficiency has a broad impact on p53 target gene expression profile; we tested more p53 targets in various functional groups and all were affected in the same trend as p21 and PUMA, albeit, to different extents (Shi and Gu, unpublished data). Among all, the most drastic change occurs on p21. in addition, p53+/+ and − / − isogenic HCT116 colon carcinoma cells were transfected with either control or DDX24-specific siRNA to induce DDX24 depletion. The considerable induction of p53 target genes was only present in HCT116 p53 wild-type cells by DDX24 depletion and no perceptible differences of p21 and puma were observed in p53 null HCT116 cells ( Figure 2c ). Therefore, the repressive effect of DDX24 on p21 and PUMA expression relies on an intact p53 pathway.
To exclude off-target of DDX24 siRNA, we ablated DDX24 in U2OS cells using four DDX24 siRNA oligos (RNA interference /DDX24 #1, #2, #3 and #4) targeting different regions of DDX24 Figure 2a was extracted, and cDNA was prepared by reverse transcription. The mRNA abundance for p21 and PUMA was assessed using quantitative real time PCR. (c) DDX24 siRNA effects on p53-dependent PUMA and p21 expression. Control or DDX24 siRNA were transfected into either p53+/+ or p53-/-HCT116 cells for 3 days, and the cell extracts were applied to western blot analysis using α-DDX24, α-p53, α-p21, α-PUMA and α-βactin antibodies. (d) DDX24 siRNA effects on p53 target PUMA and p21 with multiple DDX24-specific siRNA oligos. U2OS cells were transiently transfected with control siRNA or four DDX24-specific siRNA oligos (#1, #2, #3 and #4). Total cell lysates were analyzed by western blotting with α-DDX24, α-p53, α-p21, α-PUMA and α-β-actin antibodies. (e) p53-ser15 phosphorylation and γ-H2AX in control and DDX24 siRNAtreated U2OS cells. U2OS cells were transiently transfected with control or DDX24-specific siRNA, or U2OS cells were treated with 1 μM Doxorubicin (Dox) for 6 h. Total cell lysates were immunoblotted for p53 phosphoserine 15 (S15-phos-p53), γ-H2AX, p53, DDX24 and β-actin. messenger RNA. Again, the marked upregulation of p21 and PUMA were repeatedly shown up in all four samples with DDX24 protein level equivalently reduced ( Figure 2d ). It is worth mentioning that the slight increase of p53 protein level was observed when DDX24 is depleted from both U2OS and HCT116 cells. However, the difference in p53 protein level is not comparable to the fold change of expression level of p53 target genes when control and DDX24 siRNA-treated cells were compared. The very drastic increase in p53 transcriptional activity induced by DDX24 deficiency raised our concern of a potential p53-stabilizing stress response in DDX24-depleted cells. 30 We investigated this possibility by detecting signals of p53 serine15 (S15) phosphorylation and γ-H2AX, markers of stress-induced p53 and global genome stress, in lysates of control and DDX24 siRNAtreated U2OS cells. The cells had equivalently undetectable level of p53 S15 phosphorylation and γ-H2AX, compared with the robust induction of those in U2OS cells incubated with genotoxic drug doxorubicin (Figure 2e ). Therefore, a nonspecific stress mechanism was precluded to account for the hyperactivity of p53 in these cells. It is speculative that RNA helicase activity of DDX24, although not characterized yet, could possibly play a role in global transcription machinery. To this end, p53 messenger RNA level was evaluated by quantitative reverse transcription-PCR and found unchanged in DDX24-depleted cells (Supplementary Figure S1 ). p53 overactivity in DDX24-deficient cells is not due to altered overall cellular transcription activities. Collectively, our data demonstrate that DDX24 serves as a strong negative regulator of p53 activity.
DDX24 inhibits p300-mediated acetylation of p53
To gain mechanistic insight of DDX24-mediated repression of p53 transcription activity, we focused on the novel interaction between DDX24 and p300. As p300-mediated p53 acetylation is critical for p53 transcription activity, we speculate that DDX24 suppresses p53 transcription activation by inhibiting p300dependent acetyl transferase activity toward p53. To test this hypothesis, we assessed whether the excessive expression of DDX24 modulates p300-mediated p53 acetylation. H1299 cells were transfected with p53 and p300 simultaneously, and the cell lysates were supplemented with HDAC inhibitor trichostatin A and sirtuin inhibitor nicotinamide to enrich for p53 acetylation. As expected, when p300 was co-expressed, p53 was readily acetylated on its five carboxyl-terminal lysines (Figure 3a) . The concomitant overexpression of DDX24 protein decreased p53 acetylation level in a DDX24 dose-dependent manner (Figure 3a) . To further validate that DDX24 potentiates p300-mediated p53 acetylation under physiological settings, control and DDX24 siRNA-transfected U2OS cells were incubated with trichostatin A/nicotinamide to enrich for p53 acetylation and MG132 proteasome inhibitor to equalize p53 abundance. DDX24 knockdown substantially increased endogenous p53 acetylation level at the classic p53 C-terminal lysine 382 site, a representative of total p53 C-terminal acetylation lysine sites (Figure 3b ). Likewise, DDX24 inhibits p53 acetylation on other p300mediated lysine site K164 (Figure 3c ). However, no apparent impact on K120 acetylation of p53 was observed when DDX24 is overexpressed (Figure 3d ). Taken together, our data indicate that DDX24 modulates p53 transcriptional activity through impeding p300-mediated acetylation. Next we ask whether DDX24 influences the intrinsic HAT activity of p300, which is reflected by its autoacetylation level. 31, 32 Increasing amount of Myc-tagged DDX24 plasmids were transfected with equal amount of Flag-tagged p300 and the cell lysates were then subjected to Flag/M2 IP. The autoacetylation level on p300 was prominent when p300 was transfected alone, and the addition of DDX24 does not change the autoacetylation level even slightly (Figure 4a ). Evidently, DDX24 does not exert direct impact on the intrinsic enzymatic activity of p300.
Previous studies ascertain that p300 exists in the same complex with p53. 33 We hypothesize that DDX24 suppresses p300dependent p53 acetylation by interfering with this p300-p53/ enzyme-substrate interaction. To this end, we first confirmed the binding between p300 and p53 in an overexpression system in H1299 cells (Figure 4b ). Upon DDX24 expression, the amount of p300-bound p53 decreased markedly (Figure 4b) . As a consequence, DDX24 strongly antagonized p53 transactivation of p21 promoter in a luciferase essay (Figure 4c ). Our data gradually unraveled the mechanism underlying the repressive role of DDX24 toward the p53 activity. As diagramed in Figure 4d , DDX24 interferes with p300 catalyzed p53 acetylation by blocking p300-p53/HAT-substrate interaction.
DDX24 negatively regulates p53-mediated cell cycle arrest and senescence
To further investigate the physiological significance of DDX24-p300 interaction, we tested the effect of endogenous DDX24 in modulating p53-mediated cellular functions. U2OS cells, bearing wild-type p53, were treated with either control or DDX24-specific siRNA and incubated for 48 h to achieve satisfactory knockdown efficiency. Cells were then reseeded at identical numbers and DDX24 negatively regulates p300-p53 interplay D Shi et al allowed to grow for another 4 days, and cell proliferation rate was measured by recording cell number on each successive day. It is evident that the proliferation of DDX24-depleted cells is significantly impeded, whereas control cells double every 24 h ( Figure 5a ). As p21 is the most affected p53 targets in DDX24deficient cells, it is speculated that the altered cell growth rate in same cells is due to p21 induced G1/S cell cycle arrest. As presented in Figure 5c , 43% of the total control cells arrested at G1 phase, and DDX24 knockdown led to the significant increase of G1 population to 62%. In accordance, the reduction of S phase is drastic when DDX24 is depleted from cells (Figure 5c ). Apparently, DDX24-deficient cells underwent G1/S cell cycle arrest, presumably dependent on amplified p21 expression. We further knockdown p53 in DDX24-depleted cells, and the cell cycle arrest phenotype was reversed (Figure 5c ). The DDX24 depletion-induced cell cycle arrest is also prominent under DNA damage condition. In Figure 5b , control siRNA-treated cell, when challenged with etoposide for 48 h, underwent apoptosis reflected by the subG1 peak in the histogram of cell cycle profile. DDX24 siRNA-treated cells, under same treatment, did not undergo apoptosis but showed even more predominant G1/S arrest (Figure 5b) . Interestingly, prolonged culturing of DDX24 siRNA-treated U2OS cells ultimately resulted in enlarged and flattened cell shape, the phenotypes typical of senescence. 34 Most strikingly, DDX24 knockdown cells appeared~100% positive for β-galactosidase staining, which proves the occurrence of senescence in cells lacking DDX24 protein ( Figure 5d ). As p21 was originally discovered as a senescenceassociated gene, 35 it is not surprising that concomitant DDX24 and p53 knockdown conferred resistance to senescent phenotype (Figure 5d ). The siRNA knockdown efficiency was examined by western blotting analysis of individual targeted genes (Figure 5d, right panel) . Taken together, DDX24 negatively regulates p53-dependent G1/S cell cycle arrest and senescence.
DDX24 antagonizes p53 function to promote tumor cell growth
The primary role of p53 in tumorigenesis is to suppress tumor cell growth. To address whether DDX24 influences the suppressive function of p53 in tumor cell growth, a colony-formation assay was carried out in p53 null H1299 cells. 36 Cells were transfected with the combinations of plasmids expressing DDX24 or p53 protein (Figure 6a ). The transfected cells were reseeded at the same number, incubated for 14 days, and stained with crystal violet. As expected, the colonies formed on singly p53 expressed plate markedly decreased to 5% in comparison with the empty vector-transfected plates (Figure 6a ). Significantly, the concomitant expression of DDX24 reversed the growth suppressive effect of p53 in a dose-dependent manner (Figure 6a ). Therefore, DDX24 antagonizes the function of p53 to promote tumor cell growth. Interestingly, DDX24 is highly expressed in a wide range of breast cancer cell lines, whereas the expression level of DDX24 in normal breast cells (MCF-10A) is low (Figure 6b ), suggesting a potential role of DDX24 in breast cancer tumorigenesis presumably attributed to its negative regulatory effect on p53. To strengthen this notion, we analyzed the correlation between p53 mutation status and the expression level of DDX24 in breast tumor samples acquired from the TCGA database. As presented in Supplementary Figure S2 , the transcriptional abundance of DDX24 is lower in TP53-mutant (mut) samples than in its wild-type samples in TCGA breast cancer data sets. The difference of DDX24 expression level is statistically significant in the two groups, with a P-value of 0.0002282. The correlation of higher DDX24 expression level with the functional integrity of wild-type p53 pathway in human breast tumor data supports the significant impact of DDX24 in the p53 signaling pathway. MCF7 was selected at random to test DDX24 effect on p53 and the result validated that DDX24 repression of p53 on target p21 is not tissue or cell context specific (Figure 6c ). Taken together, the counteractive role of DDX24 in p53 biology and the frequently aberrant expression of DDX24 protein throughout breast tumor cells suggest a putative oncogenic role of DDX24 in breast cancer tumorigenesis.
DISCUSSION
In this report, we described the identification of DDX24 as a novel and negative regulatory factor of p53. We have demonstrated that DDX24 has an inhibitory role in p53 transcriptional activity and subsequently in p53 controlled cell growth arrest and senescence. The underlying mechanism by which DDX24 regulates p53 lies in the mass spectrometry identified original DDX24-p300 interaction. DDX24 competes with p53 for p300 interaction, and therefore exhibits an adverse effect on p300 catalyzed p53 acetylation. DDX24 is often aberrantly overexpressed in breast cancer cells, suggesting a potential role in tumorigenesis by antagonizing the tumor suppressor function of p53.
Our data strongly support the role of DDX24 as a negative regulator of p53. However, the precise mechanism by which DDX24 suppresses p53 function requires further elucidation. It is well accepted that acetylation and ubiquitination are counteracting processes that compete for the same lysine residues on p53. As the forced expression of DDX24 represses p53 acetylation, p53 ubiquitination will be promoted on the same p53 lysines. This hypothesis was confirmed as DDX24 overexpression promotes p53 ubiquitination in in vivo ubiquitination assay, adding one more layer of p53 regulation via DDX24 (Supplemetary Figure S3 ). When U2OS and HCT116 cells were treated with three rounds of DDX24 siRNA, knockdown efficiency was maximized and the DDX24 protein was completely depleted from cells. Under this condition, the increased p53 protein level in DDX24-depleted cells becomes more perceptible, as a result of prolonged half-life of p53 protein (Supplemetary Figure S4) . Altogether, DDX24 acts as a double-edged sword, repressing p53 acetylation and simultaneously promoting p53 ubiquitination. Of note, another group recently showed that DDX24 knockdown activates p53 through a distinctive mechanism. 37 It was presented that the depletion of DDX24 induces nucleolar stress, which in turn stabilizes p53 protein and activates p53 activity. 37 To what extent these two mechanisms contribute to the regulation of p53 activity is of great interest for further exploration. In fact, as shown in Figure 4c , p53mediated transactivation of p21 promoter can be severely inhibited by DDX24 overexpression, indicating that DDX24mediated effect on p53 is direct, rather than indirectly through nucleolar stress. Moreover, DDX24-mediated repression of p53 activity is significantly abrogated when the acetylation-defective mutant p53-6KR was used, suggesting that DDX24-mediated effects act at least, in part, by modulating p53 acetylation (Supplemetary Figure S5) . The discovery of DDX24 as a novel modulator of p300-p53 axis adds extra complexity to an already complicated molecular network centered on p300 and p53 proteins. p300-p53 axis is regulated through multiple mechanisms including p53 serine15 phosphorylation via ATM, MDM2/MDMX competition for p53 transactivation domain, and the interaction with other cofactors. 38 DDX24 may interact with numerous cofactors of p300/p53 to complement or to antagonize their functions. For example, we have observed that DDX24 was linked to MDM2. As shown in Supplementary Figure S6 , the inhibitory effect of DDX24 on p53-mediated transcriptional activation is significantly abrogated when the cells were pretreated with Nutlin-3a, which effectively blocks p53-Mdm2 interaction, indicating that DDX24 may act in part through modulating the p53-Mdm2 interaction to weaken p53 activity. A recent study found that MDM2 catalyzes polyubiquitin chains onto DDX24 but does not lead to proteasome degradation of DDX24 protein. 37 It is intriguing to investigate what signaling cascade this polyubiquitinated form of DDX24 involves and how it affects p300-p53 complex composition and p53 activity. Furthermore, DDX24 is expected to antagonize the function of positive regulators of p300-p53 axis, such as junction mediating and regulatory protein (JMY) and Strap, interacting with p300 and promoting p53 acetylation. 38 We hypothesize that DDX24 functions as a component in a multi-protein complex to control p53 acetylation and the regulatory role of DDX24 might be extended to other p300 substrates. Until now, little is known about modification or regulation of DDX24 protein itself. The elucidation of how DDX24 is regulated at the transcriptional, translational and even post-translational level under various contexts will certainly help to gain a greater understanding of the multiple regulatory levels that p53 is subjected to.
Recently, the Barber group demonstrated DDX24 as a negative modulator of innate immune signaling. 39 DDX24 is induced in response to interferon treatment, disrupting the association between Fas (TNFRSF6)-associated via death domain (FADD) and receptor (TNFRSF)-interacting serine-threonine kinase 1 (RIPK1) and causing inhibition of the NF-κB pathway required for optimal interferon production. 39 This observation, combined with our discovery of DDX24 as a negative modulator of p53 pathway, indicates that DDX24 potentially bridge the interplay between NF-κB and p53 signaling pathways. It is well accepted that the crosstalk between p53 and NF-κB pathways has important roles in tumorigenesis. 40 DDX24 will be another example of signaling molecules, like MDM2 and Wip1, to link p53 and NF-κB pathway. [41] [42] [43] A detailed study of the interplay between these two signaling pathways through DDX24 will undoubtedly uncover new complexities in p53 biology.
The DEAD box protein group has 36 identified family members throughout the human genome and they are presumably involved in RNA metabolism. 19 Emerging evidence links this family of proteins to cancer development and progression. 19, 21, 23 Dysregulation of DEAD box proteins were identified in diverse cancer types, for example, DDX3 in quamous cell carcinoma and DDX6 in colon cancer. 21, 25, [44] [45] [46] In addition, several DEAD box proteins are reported to form complexes with cancer proteins: DDX3 with casein kinase 1 in regulating β-catenin signaling pathway, for instance. 24 Besides, DDX5 and DDX17 have been established as positive regulators of p53 through the direct contact with transcriptional machinery at p53 target promoters. 26 In contrast, DDX24 is the first identified negative regulator of p53 from the DEAD box protein family and modulates p53 activity with distinctive mechanisms. In this report, we also propose that DDX24 might be involved in the tumorigenesis of breast cancer. Further study is required to determine the extent of contribution and the exact role of DDX24 in neoplastic transformation in animal models. DDX24 is overexpressed in breast cancer cells but at low levels in non-cancerous cells, making DDX24 a potentially attractive cancer therapeutic target.
MATERIALS AND METHODS
Colony-formation assay H1299 cells were transfected with either empty or PCIN4-Flag-p53 and DDX24 expression plasmids for 48 h. Cells were then seeded at the density of 1000 cells per dish and cultured under the selection of G418 (1 mg/ml) for 14 days. Cells were stained with crystal violet solution and colonies were counted.
Senescence-associated-β-galactosidase staining Cells were fixed in 3% formaldehyde for 5 min RT, washed three times with PBS, and then incubated at 37°C for 16 h with fresh senescence-associated-β-galactosidase stain solution (1 mg/ml 5-bromo-4-chloro-3-indolyl β-d-galactosidase, 40 mM citric acid/sodium phosphate, pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl and 2 mM MgCl 2 ). 47 All reagents, antibodies and other Materials and Methods are described in the Supplementary Information.
